Biora licenses preeclampsia rule-out test for commercial development

Biora Therapeutics announced it has completed an agreement to license its Preecludia rule-out test for preeclampsia to Avero Diagnostics, formerly Northwest Pathology, for commercial development. "We have been impressed with the Avero team’s execution on several diagnostic assets, and we are excited to again partner with them to commercialize this assay, which we believe will offer providers a new screening aid in an area of great unmet need," said Adi Mohanty, Chief Executive Officer of Biora Therapeutics. "As we have shown, we remain committed to value creation from all our assets while Biora focuses on the progress of its therapeutics pipeline." Under the terms of the agreement, Avero Diagnostics receives rights to assets and intellectual property related to the Preecludia test. Biora will receive commercial milestone payments and low double-digit royalties on net sales.